In this episode of Health Insights, Dr. Holly Atkinson sits down with Dr. Harris Foster to discuss overactive bladder treatment and what medications may be the best fit to relieve your OAB symptoms. OAB is thought to occur because of involuntary contractions of the bladder. That mechanism is via nerves and primarily is driven by a substance called acetylcholine, which attaches to the muscle of the bladder and causes it to contract. To treat OAB, you're blocking the interaction between that substance and the bladder muscle to reduce the increased contractions.
There are a host of drugs used to treat OAB, none of which are necessarily better than the other. You'll need to work closely with your doctor to figure out which OAB medications are best for you.
Apostolidis A. Neuromodulation for intractable OAB. Neurourol Urodyn 2011;30(50):766-70.
Athanasopoulos A, Chapple C, Fowler C, Gratzke C, Kaplan S, Stief C, Tubaro A. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update.Eur Urol 2011;60(1):94-105. Epub 2011 Apr 9.
Carr LK. Botulinum toxin A should not be first-line therapy for overactive bladder. Can Urol Assoc J 2011;5(3):204-5.
Dmochowski RR, Gomelsky A.Update on the treatment of overactive bladder. Curr Opin Urol 2011;21(4):286-90.
Heidler S, Mert C, Temml C, Madersbacher S. The natural history of the overactive bladder syndrome in females: A long-term analysis of a health screening project. Neurourol Urodyn 2011, Jun 9. [Epub ahead of print]
Robinson D, Cardozo L. Estrogens and the lower urinary tract. Neurourol Urodyn 2011;30(50):754-7.
Schnitzler A, Genet F, Durand MC, Roche N, Bensmail D, Chartier-Kastler E, Denys P.Pilot study evaluating the safety of intradetrusor injections of botulinum toxin type A: Investigation of generalized spread using single-fiber EMG.Neurourol Urodyn 2011, Jun 9. doi: 10.1002/nau.21103. [Epub ahead of print]
Sexton CC, Notte SM, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D, Coyne KS.Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 2011;65(5):567-85.
Weiss JP, Blaivas JG, Bliwise DL, Dmochowski RR, Dubeau CE, Lowe FC, Petrou SP, Van Kerrebroeck PE , Rosen RC, Wein AJ. The evaluation and treatment of nocturia: a consensus statement.BJU Int 2011;108(1):6-21.
©2005-2017 HealthiNation, Inc. All rights reserved. HealthiNation does not provide medical advice, diagnosis or treatment.